Page last updated: 2024-08-17

spironolactone and candesartan

spironolactone has been researched along with candesartan in 45 studies

Research

Studies (45)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	22 (48.89)	29.6817
2010's	20 (44.44)	24.3611
2020's	3 (6.67)	2.80

Authors

Authors	Studies
Andricopulo, AD; Moda, TL; Montanari, CA	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Hoagland, KM; Ito, O; Ito, S; Omata, K; Roman, RJ	1
Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D	1
Ageloff, S; Beutler, KT; Brooks, HL; Fenton, RA; Knepper, MA; Masilamani, S; Nielsen, J; Packer, RK; Turban, S	1
Brown, NJ; Kumar, S; Murphey, LJ; Sawathiparnich, P; Vaughan, DE	1
Gama, MG; Rocha, G	1
Hara, Y; Imaki, T; Naruse, M; Nishikawa, T; Sato, A; Takano, K; Tanabe, A; Tsuchiya, K	1
Omura, T; Yoshikawa, J; Yoshiyama, M	1
Kochsiek, K	1
Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K	1
Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F	1
Fukushima Kusano, K; Hisamatsu, K; Ishihara, K; Kajiya, M; Miura, A; Miura, D; Miura, R; Morita, H; Nagase, S; Nakamura, K; Ohe, T	1
Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S	1
Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T	1
Chan, AK; Chan, WW; Lam, W; Lam, YY; Sanderson, JE; So, N; Wang, M; Wang, T; Wong, JT; Wu, EB; Yeung, L; Yip, G; Yu, CM; Zhang, Y	1
Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A	1
Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Sato, Y; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T	1
Granger, CB; McMurray, JJ; Michelson, EL; Olofsson, B; Pfeffer, MA; Puu, M; Solomon, SD; Swedberg, K; Weir, RA; Yusuf, S	1
Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M	1
Homma, I; Iigaya, K; Kobayashi, Y; Minoura, Y; Onimaru, H	1
Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J	1
Frohlich, ED; Susic, D; Varagic, J	1
Katayama, A; Makino, H; Matsumoto, Y; Nasu, Y; Otsuka, F; Tanabe, K; Tsukamoto, N; Yamanaka, R	1
Hanawa, H; Kobayashi, D; Kuroda, T; Murakami, S; Nakano, M; Narita, I; Oda, M; Wada, Y	1
Ariti, CA; Collier, TJ; Pocock, SJ; Wang, D	1
Cheng, Y; Demura, M; Karashima, S; Takata, H; Takeda, Y; Yagi, K; Yamagishi, M; Yoneda, T; Zhu, A	1
Fujita, T; Hirooka, K; Itano, T; Lei, B; Liu, Y; Nakamura, T; Nishiyama, A; Shiraga, F; Zhang, J	1
Axelsson, J; Oberg, CM; Rippe, A; Rippe, B	1
Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R	1
Gabor, A; Leenen, FH	1
Baumwol, J; Lam, K; Maiorana, AJ	1
Rossignol, P; Zannad, F	1
El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A	1
Amann, K; Brand, S; Mandel, P; Schupp, N; Zimnol, A	1
Goto, M; Hasebe, N; Takahashi, F; Wada, Y	1
Rickenbacher, P	1
Anand, IS; Carson, PE; Desai, AS; Docherty, KF; Granger, CB; Jhund, PS; Komajda, M; McKelvie, RS; McMurray, JJV; Petrie, MC; Pfeffer, MA; Shen, L; Solomon, SD; Swedberg, K; Zile, MR	1
Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H	1
Anand, IS; Carson, P; Claggett, BL; Cunningham, JW; Desai, AS; Jhund, PS; John, JE; Kober, L; Lewis, EF; McMurray, JJV; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Yusuf, S; Zile, MR	1
Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J	1

Reviews

4 review(s) available for spironolactone and candesartan

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2004, Volume: 124, Issue:2 Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Spironolactone; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling	2004
[Heart failure with "mid-range" ejection fraction: a new clinical entity?] Therapeutische Umschau. Revue therapeutique, 2018, Volume: 75, Issue:3 Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Natriuretic Peptides; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Syndrome; Tetrazoles; Valsartan	2018
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. The American journal of cardiology, 2020, 04-15, Volume: 125, Issue:8 Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan	2020

Trials

10 trial(s) available for spironolactone and candesartan

Article	Year
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:2 Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2002
Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:8 Topics: Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Diuretics; Electrolytes; Female; Fibrinolysis; Furosemide; Hemodynamics; Humans; Male; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Potassium Chloride; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Single-Blind Method; Spironolactone; Tetrazoles	2003
[Angiotensin receptor blockers in heart failure. CHARM Study]. Der Internist, 2004, Volume: 45, Issue:9 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiac Output, Low; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Ventricular Dysfunction, Left	2004
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:8 Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Echocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Tetrazoles; Ventricular Remodeling	2006
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. Journal of the American College of Cardiology, 2007, Aug-14, Volume: 50, Issue:7 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone; Tetrazoles; Treatment Outcome; Ultrasonography; Ventricular Remodeling	2007
Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007, Volume: 48, Issue:12 Topics: 3-Iodobenzylguanidine; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Synergism; Echocardiography; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Spironolactone; Sympathetic Nervous System; Tetrazoles; Ventricular Function, Left; Ventricular Remodeling	2007
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa European journal of heart failure, 2008, Volume: 10, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Creatinine; Drug Therapy, Combination; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Spironolactone; Tetrazoles	2008
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2009, Volume: 29, Issue:5 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Eplerenone; Female; Humans; Lisinopril; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Obesity; Prospective Studies; Proteinuria; Spironolactone; Tetrazoles	2009
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2013, Volume: 61, Issue:4 Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Drug Therapy, Combination; Echocardiography; Female; Furosemide; Heart Function Tests; Hong Kong; Humans; Male; Predictive Value of Tests; Prognosis; Propanolamines; Ramipril; Spironolactone; Survival Rate; Tenascin; Tetrazoles; Turkey; Ventricular Remodeling	2013
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC. Heart failure, 2020, Volume: 8, Issue:8 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Irbesartan; Male; Morbidity; Myocardial Infarction; Risk Factors; Spironolactone; Stroke Volume; Systole; Tetrazoles	2020

Other Studies

31 other study(ies) available for spironolactone and candesartan

Article	Year
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid. American journal of physiology. Regulatory, integrative and comparative physiology, 2001, Volume: 280, Issue:3 Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Bradykinin; Bradykinin Receptor Antagonists; Captopril; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Desoxycorticosterone; Enalapril; Enzyme Inhibitors; Hydroxyeicosatetraenoic Acids; Kidney; Kidney Cortex; Kidney Medulla; Male; Microsomes; Mixed Function Oxygenases; NADPH-Ferrihemoprotein Reductase; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Spironolactone; Tetrazoles	2001
Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:5 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzothiadiazines; Bicarbonates; Biphenyl Compounds; Diuretics; Epithelial Sodium Channels; Gene Expression Regulation; Immunoblotting; Infusion Pumps; Injections, Subcutaneous; Kidney; Kidney Cortex; Kidney Medulla; Kidney Tubules, Distal; Male; Mineralocorticoid Receptor Antagonists; Potassium; Protein Subunits; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium Channels; Sodium Chloride Symporter Inhibitors; Sodium Chloride Symporters; Sodium Chloride, Dietary; Spironolactone; Symporters; Tetrazoles; Time Factors	2003
The CHARM programme. Lancet (London, England), 2003, Nov-15, Volume: 362, Issue:9396 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cause of Death; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Tetrazoles	2003
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. Journal of hypertension, 2004, Volume: 22, Issue:5 Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Weight; Cardiomegaly; Cardiotonic Agents; Collagen Type I; Collagen Type III; Drug Synergism; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; RNA, Messenger; Spironolactone; Tetrazoles	2004
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. European journal of heart failure, 2005, Volume: 7, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan	2005
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. The Kobe journal of medical sciences, 2005, Volume: 51, Issue:1-2 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Drug Therapy, Combination; Female; Humans; Hyperkalemia; Hypertension; Middle Aged; Nephrosclerosis; Spironolactone; Tetrazoles	2005
Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. Journal of pharmacological sciences, 2006, Volume: 101, Issue:3 Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Captopril; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Female; Humans; Leukocytes, Mononuclear; Male; Mineralocorticoid Receptor Antagonists; Spironolactone; Tetrazoles; Tumor Necrosis Factor-alpha	2006
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology, 2007, Volume: 148, Issue:4 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Cyclic N-Oxides; Eplerenone; Gene Expression Regulation; Hypertension; Inflammation Mediators; Male; Models, Biological; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles	2007
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. American journal of hypertension, 2007, Volume: 20, Issue:10 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Endothelium, Vascular; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Tetrazoles	2007
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovascular research, 2008, Jul-01, Volume: 79, Issue:1 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation	2008
Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone. American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 297, Issue:3 Topics: Aldosterone; Anesthetics, Local; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Fibers, Preganglionic; Benzimidazoles; Biphenyl Compounds; Eplerenone; Excitatory Postsynaptic Potentials; Female; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Spironolactone; Synaptic Transmission; Tetrazoles; Tetrodotoxin; Time Factors	2009
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess. American journal of physiology. Heart and circulatory physiology, 2010, Volume: 298, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiomyopathies; Cardiovascular System; Eplerenone; Hypertension; Hypertrophy; Kidney; Male; Mineralocorticoid Receptor Antagonists; Quinapril; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Regional Blood Flow; Renin-Angiotensin System; Sodium Chloride, Dietary; Spironolactone; Tetrahydroisoquinolines; Tetrazoles; Ventricular Dysfunction, Left	2010
Unexpected occurrence of adrenal Cushing's syndrome in a patient with systemic lupus erythematosus. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:5 Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Angiomyolipoma; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cushing Syndrome; Drug Therapy, Combination; Female; Humans; Hypertension; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Nifedipine; Prednisolone; Ribonucleosides; Spironolactone; Tetrazoles	2011
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents. Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:5 Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug Therapy, Combination; Dyspnea; Etanercept; Female; Furosemide; Glucocorticoids; Hand; Heart Failure; Humans; Immunoglobulin G; Lung Diseases, Interstitial; Natriuretic Peptide, Brain; Propanolamines; Radiography; Receptors, Tumor Necrosis Factor; Rheumatoid Factor; Ribonucleosides; Scleroderma, Systemic; Spironolactone; Sulfasalazine; Tetrazoles; Treatment Outcome	2011
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European heart journal, 2012, Volume: 33, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; Cardiac Catheterization; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination; Eplerenone; Heart Failure; Hospitalization; Humans; Matched-Pair Analysis; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Risk Factors; Spironolactone; Tetrazoles	2012
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Peripheral Nerves; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Tetrazoles	2012
Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. Experimental eye research, 2012, Volume: 96, Issue:1 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Survival; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Reperfusion Injury; Retinal Diseases; Spironolactone; Tetrazoles	2012
Rapid, dynamic changes in glomerular permeability to macromolecules during systemic angiotensin II (ANG II) infusion in rats. American journal of physiology. Renal physiology, 2012, Sep-15, Volume: 303, Issue:6 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Ficoll; Glomerular Filtration Rate; Infusions, Intravenous; Kidney Glomerulus; Male; Mineralocorticoid Receptor Antagonists; Nimodipine; Permeability; Rats; Rats, Wistar; Spironolactone; Tetrazoles; Vasodilator Agents	2012
Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 61, Issue:5 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Eplerenone; Glutamic Acid; Heart Rate; Hypertension; Infusions, Intravenous; Infusions, Intraventricular; Kynurenic Acid; Male; Mineralocorticoid Receptor Antagonists; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Glutamate; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Tetrazoles	2013
Successful explant of a continuous-flow left ventricular assist device after two years of circulatory support. Artificial organs, 2014, Volume: 38, Issue:9 Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Diuretics; Exercise Test; Heart Ventricles; Heart-Assist Devices; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Spironolactone; Tetrazoles	2014
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation, 2015, Jan-06, Volume: 131, Issue:1 Topics: Benzimidazoles; Biphenyl Compounds; Female; Fluorobenzenes; Geography; Heart Failure; Humans; Internationality; Irbesartan; Male; Mineralocorticoid Receptor Antagonists; Patients; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Stroke Volume; Sulfonamides; Tetrazoles	2015
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. European journal of pharmacology, 2014, Dec-05, Volume: 744 Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Inflammation; Kidney; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Spironolactone; Streptozocin; Superoxides; Tetrazoles; Transforming Growth Factor beta	2014
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors. PloS one, 2014, Volume: 9, Issue:12 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Deoxyguanosine; DNA Damage; DNA Repair; Enzyme Activation; Eplerenone; Guanosine; Heart; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles	2014
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Creatinine; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension, Malignant; Male; Nifedipine; Nitroglycerin; Obesity; Renal Insufficiency; Spironolactone; Tetrazoles; Treatment Outcome; Vasodilator Agents	2015
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC. Heart failure, 2019, Volume: 7, Issue:5 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiac Pacing, Artificial; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Pacemaker, Artificial; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Spironolactone; Stroke Volume; Tetrazoles; Ventricular Dysfunction, Left	2019
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Therapeutic innovation & regulatory science, 2022, Volume: 56, Issue:1 Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Spironolactone; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left	2022